Witmer Char M, Lambert Michele P, O'Brien Sarah H, Neunert Cindy
Divisions of Hematology, Departments of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
Pediatr Blood Cancer. 2016 Jul;63(7):1227-31. doi: 10.1002/pbc.25961. Epub 2016 Feb 29.
Recent pediatric immune thrombocytopenia (ITP) guidelines have significantly altered and are encouraging an observational approach for patients without significant bleeding regardless of their platelet count.
This retrospective multicenter cohort study utilized the Pediatric Health Information Systems (PHIS) administrative database. Subjects were 6 months to 18 years of age, admitted to a PHIS hospital between January 1, 2008 and September 30, 2014, with a primary diagnosis code for ITP. International Classification of Disease, Ninth Revision, Clinical Modification Code (ICD-9-CM) discharge codes identified significant bleeding. Pharmaceutical billing codes identified the use of pharmacologic therapy for ITP. Clinical management during preguideline admissions (January 1, 2008 to August 31, 2011) was compared to postguideline admissions (September 1, 2011 to September 30, 2014).
A total of 4,937 subjects met inclusion criteria with a mean age of 6.2 (SD 5) years; 93.4% (4,613/4,937) received pharmacologic treatment for ITP but only 14.2% (699/4,937) had ICD-9-CM codes for significant bleeding; 11.5% (570/4,937) of subjects were readmitted. In comparing pre- versus postguideline time periods, the proportion of subjects receiving ITP pharmacologic treatment did not change (92.9% vs. 94.1%; P = 0.26). A decrease was found in the proportion of bone marrows performed (9.7% vs. 6.4%; P < 0.001) and length of stay (2.3 vs. 2 days; P < 0.001). The proportion of ITP admissions from 2012 to 2014 was modestly decreased when compared to 2008-2010 (12.9 vs. 14.5/10,000 PHIS admissions, P < 0.001).
Despite guidelines and evidence that supports a watchful waiting approach for pediatric patients with ITP, a large proportion of inpatients without significant bleeding are still receiving pharmacologic therapy. Continued efforts are needed to address why inpatient U.S. practice patterns are so discrepant from current treatment guidelines.
近期的儿童免疫性血小板减少症(ITP)指南有显著变化,鼓励对无明显出血的患者采取观察性治疗方法,无论其血小板计数如何。
这项回顾性多中心队列研究使用了儿科健康信息系统(PHIS)管理数据库。研究对象为6个月至18岁,于2008年1月1日至2014年9月30日期间入住PHIS医院,且主要诊断代码为ITP的患者。国际疾病分类第九版临床修订本代码(ICD - 9 - CM)出院代码用于确定明显出血情况。药品计费代码用于确定ITP药物治疗的使用情况。比较了指南发布前(2008年1月1日至2011年8月31日)和指南发布后(2011年9月1日至2014年9月30日)住院期间的临床管理情况。
共有4937名受试者符合纳入标准,平均年龄为6.2(标准差5)岁;93.4%(4613/4937)的患者接受了ITP药物治疗,但只有14.2%(699/4937)有ICD - 9 - CM代码表示有明显出血;11.5%(570/4937)的受试者再次入院。在比较指南发布前后的时间段时,接受ITP药物治疗的受试者比例没有变化(92.9%对94.1%;P = 0.26)。骨髓检查的比例有所下降(9.7%对6.4%;P < 0.001),住院时间也有所缩短(2.3天对2天;P < 0.001)。与2008 - 2010年相比,2012 - 2014年ITP住院患者的比例略有下降(12.9对14.5/10000例PHIS住院患者,P < 0.001)。
尽管有指南和证据支持对ITP儿科患者采取观察等待的方法,但很大一部分无明显出血的住院患者仍在接受药物治疗。仍需继续努力,以解决美国住院患者的治疗模式为何与当前治疗指南存在如此大差异的问题。